ARTICLE | Company News

Hemispherx, Swiss Federal Department of Defense, Civil Protection and Sports (DDPS) infectious news

September 22, 2014 7:00 AM UTC

Hemispherx expanded a research deal with the Swiss agency to test Hemispherx's Alferon N Injection and Ampligen rintatolimod against the Ebola virus. DDPS's Swiss Institute for Nuclear, Biological, Chemical Protection will conduct the studies under a data exchange agreement between the Swiss Surgeon General and the U.S. Department of Defense. Hemispherx partnered with the Swiss agency earlier this year to test Alferon against wild-type and Tamiflu oseltamivir-resistant H7N9 influenza virus (see BioCentury, May 26). ...